A Novel Subtype Based on Driver Methylation-transcription in Lung Adenocarcinoma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2024 May 22

PMID 38777866

Authors

Xin Wang

Zhenyi Xu

Shuang Zhao

Jiali Song

Yipei Yu

Han Yang

Yan Hou

Affiliations

Soon will be listed here.

Abstract

Aims: To identify driver methylation genes and a novel subtype of lung adenocarcinoma (LUAD) by multi-omics and elucidate its molecular features and clinical significance.

Methods: We collected LUAD patients from public databases, and identified driver methylation genes (DMGs) by MethSig and MethylMix algrothms. And novel driver methylation multi-omics subtypes were identified by similarity network fusion (SNF). Furthermore, the prognosis, tumor microenvironment (TME), molecular features and therapy efficiency among subtypes were comprehensively evaluated.

Results: 147 overlapped driver methylation were identified and validated. By integrating the mRNA expression and methylation of DMGs using SNF, four distinct patterns, termed as S1-S4, were characterized by differences in prognosis, biological features, and TME. The S2 subtype showed unfavorable prognosis. By comparing the characteristics of the DMGs subtypes with the traditional subtypes, S3 was concentrated in proximal-inflammatory (PI) subtype, and S4 was consisted of terminal respiratory unit (TRU) subtype and PI subtype. By analyzing TME and epithelial mesenchymal transition (EMT) features, increased immune infiltration and higher expression of immune checkpoint genes were found in S3 and S4. While S4 showed higher EMT score and expression of EMT associated genes, indicating S4 may not be as immunosensitive as the S3. Additionally, S3 had lower TIDE and higher IPS score, indicating its increased sensitivity to immunotherapy.

Conclusion: The driver methylation-related subtypes of LUAD demonstrate prognostic predictive ability that could help inform treatment response and provide complementary information to the existing subtypes.

References

Niemira M, Collin F, Szalkowska A, Bielska A, Chwialkowska K, Reszec J . Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA). Cancers (Basel). 2019; 12(1). PMC: 7017323. DOI: 10.3390/cancers12010037. View

De Smet C . DNA methylation profiling in early lung adenocarcinoma to predict response to immunotherapy. Transl Lung Cancer Res. 2023; 12(4):657-660. PMC: 10183395. DOI: 10.21037/tlcr-23-96. View

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

Hashiguchi T, Miyoshi H, Nakashima K, Yokoyama S, Matsumoto R, Murakami D . Prognostic impact of GATA binding protein-3 expression in primary lung adenocarcinoma. Hum Pathol. 2017; 63:157-164. DOI: 10.1016/j.humpath.2017.02.024. View

Gu M, Xu T, Chang P . and co-mutations create divergent immune signatures in lung adenocarcinomas. Ther Adv Med Oncol. 2021; 13:17588359211006950. PMC: 8072935. DOI: 10.1177/17588359211006950. View

Shen M, Qi R, Ren J, Lv D, Yang H . Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer. Front Oncol. 2022; 11:780655. PMC: 8766810. DOI: 10.3389/fonc.2021.780655. View

Pan H, Renaud L, Chaligne R, Bloehdorn J, Tausch E, Mertens D . Discovery of Candidate DNA Methylation Cancer Driver Genes. Cancer Discov. 2021; 11(9):2266-2281. PMC: 8419066. DOI: 10.1158/2159-8290.CD-20-1334. View

Gillette M, Satpathy S, Cao S, Dhanasekaran S, Vasaikar S, Krug K . Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell. 2020; 182(1):200-225.e35. PMC: 7373300. DOI: 10.1016/j.cell.2020.06.013. View

Hirsch F, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K . PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2016; 12(2):208-222. DOI: 10.1016/j.jtho.2016.11.2228. View

10.

Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O . Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021; 39(6):845-865.e7. DOI: 10.1016/j.ccell.2021.04.014. View

11.

Kreitmaier P, Katsoula G, Zeggini E . Insights from multi-omics integration in complex disease primary tissues. Trends Genet. 2022; 39(1):46-58. DOI: 10.1016/j.tig.2022.08.005. View

12.

Oshi M, Kim T, Tokumaru Y, Yan L, Matsuyama R, Endo I . Enhanced DNA Repair Pathway is Associated with Cell Proliferation and Worse Survival in Hepatocellular Carcinoma (HCC). Cancers (Basel). 2021; 13(2). PMC: 7830462. DOI: 10.3390/cancers13020323. View

13.

Wu H, Xu H, Huang S, Tang Y, Tang J, Zhou H . mA-binding protein IGF2BP1 promotes the malignant phenotypes of lung adenocarcinoma. Front Oncol. 2022; 12:989817. PMC: 9554348. DOI: 10.3389/fonc.2022.989817. View

14.

Guidry K, Vasudevaraja V, Labbe K, Mohamed H, Serrano J, Guidry B . DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome. Clin Cancer Res. 2022; 28(17):3824-3835. DOI: 10.1158/1078-0432.CCR-22-0391. View

15.

Skoulidis F, Li B, Dy G, Price T, Falchook G, Wolf J . Sotorasib for Lung Cancers with p.G12C Mutation. N Engl J Med. 2021; 384(25):2371-2381. PMC: 9116274. DOI: 10.1056/NEJMoa2103695. View

16.

Klemm F, Joyce J . Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2014; 25(4):198-213. PMC: 5424264. DOI: 10.1016/j.tcb.2014.11.006. View

17.

Mak M, Tong P, Diao L, Cardnell R, Gibbons D, William W . A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2015; 22(3):609-20. PMC: 4737991. DOI: 10.1158/1078-0432.CCR-15-0876. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Park K, Haura E, Leighl N, Mitchell P, Shu C, Girard N . Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021; 39(30):3391-3402. PMC: 8791812. DOI: 10.1200/JCO.21.00662. View

20.

Cedoz P, Prunello M, Brennan K, Gevaert O . MethylMix 2.0: an R package for identifying DNA methylation genes. Bioinformatics. 2018; 34(17):3044-3046. PMC: 6129298. DOI: 10.1093/bioinformatics/bty156. View